Technical Analysis for SVRA - Savara, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 3.67% | |
| Volume Surge | Other | 3.67% | |
| Lower Bollinger Band Walk | Weakness | 3.67% | |
| Wide Bands | Range Expansion | 3.67% | |
| Oversold Stochastic | Weakness | 3.67% | |
| New 52 Week Closing Low | Bearish | 10.37% | |
| Calm After Storm | Range Contraction | 10.37% | |
| Lower Bollinger Band Walk | Weakness | 10.37% | |
| Wide Bands | Range Expansion | 10.37% | |
| Down 3 Days in a Row | Weakness | 10.37% |
| Alert | Time |
|---|---|
| Up 5% | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 3 hours ago |
| Up 3% | about 4 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
| Up 2% | about 4 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
Savara, Inc. Description
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Clinical Development Heart Failure Stage Pharmaceutical Respiratory Diseases Cystic Fibrosis Heart Disease Staphylococcus Aureus Lung Infection Methicillin Treatment Of Heart Failure Vancomycin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.7 |
| 52 Week Low | 2.815 |
| Average Volume | 1,464,084 |
| 200-Day Moving Average | 4.38 |
| 50-Day Moving Average | 3.80 |
| 20-Day Moving Average | 3.52 |
| 10-Day Moving Average | 3.43 |
| Average True Range | 0.26 |
| RSI (14) | 38.27 |
| ADX | 24.19 |
| +DI | 20.15 |
| -DI | 24.93 |
| Chandelier Exit (Long, 3 ATRs) | 3.51 |
| Chandelier Exit (Short, 3 ATRs) | 3.60 |
| Upper Bollinger Bands | 4.20 |
| Lower Bollinger Band | 2.83 |
| Percent B (%b) | 0.22 |
| BandWidth | 38.98 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.12 |
| MACD Histogram | -0.0684 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.50 | ||||
| Resistance 3 (R3) | 3.48 | 3.33 | 3.44 | ||
| Resistance 2 (R2) | 3.33 | 3.24 | 3.34 | 3.42 | |
| Resistance 1 (R1) | 3.23 | 3.18 | 3.28 | 3.25 | 3.40 |
| Pivot Point | 3.09 | 3.09 | 3.11 | 3.10 | 3.09 |
| Support 1 (S1) | 2.99 | 2.99 | 3.04 | 3.01 | 2.86 |
| Support 2 (S2) | 2.84 | 2.93 | 2.85 | 2.84 | |
| Support 3 (S3) | 2.74 | 2.84 | 2.82 | ||
| Support 4 (S4) | 2.76 |
